TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS

This invention provides specifically formulated LFA-I antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-I antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention al...

Full description

Saved in:
Bibliographic Details
Main Authors BURNIER, John, GADEK, Thomas
Format Patent
LanguageEnglish
French
German
Published 26.08.2020
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TRAPPING
Online AccessGet full text

Cover

More Information
Summary:This invention provides specifically formulated LFA-I antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-I antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-I topical formulations of the present invention.
Bibliography:Application Number: EP20190191575